Comparison of the Effect of Age ( < 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or Ticagrelor) in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention (from the RE-DUAL PCI Trial)

The RE-DUAL PCI trial reported that dabigatran dual therapy (110/150 mg twice daily, plus clopidogrel or ticagrelor) reduced bleeding events versus warfarin triple therapy (warfarin plus aspirin and clopidogrel or ticagrelor) in patients with atrial fibrillation who underwent percutaneous coronary intervention, with noninferiority in composite thromboembolic events. In this prespecified analysis, risks of first major or clinically relevant nonmajor bleeding event and composite end point of death, thromboembolic events, or unplanned revascularization were compared between dabigatran dual therapy and warfarin triple therapy in older ( ≥ 75 years) and younger (

Source: The American Journal of Cardiology - December 8, 2019 Category: Cardiology Authors: Jurrien M. ten Berg, Philippe Gabriel Steg, Deepak L. Bhatt, Stefan H. Hohnloser, Anne de Veer, Matias Nordaby, Corinna Miede, Takeshi Kimura, Gregory Y.H. Lip, Jonas Oldgren, Christopher P. Cannon, RE-DUAL PCI Steering Committee and Investigators Source Type: research